HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $29
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Immunovant (NASDAQ:IMVT) and raises the price target from $27 to $29.
July 18, 2023 | 10:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunovant's price target has been raised from $27 to $29 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Immunovant. This could potentially lead to an increase in the stock's price in the short term as it may boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100